ARQT vs DVA
Arcutis Biotherapeutics, Inc. vs DaVita — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
70
Buy
VS
| Metric | ARQT | DVA |
|---|
| AI Score |
70
|
53
|
| Price |
$24.85
|
$177.63
|
| P/E Ratio |
112.23×
|
15.18×
|
| ROE |
-8.5%
|
-114.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
31.0%
|
| Debt / Equity |
0.52×
|
-14.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
33.0
|
28.1
|
| Beta |
1.526
|
0.87
|
| Expected Upside |
+2.6%
|
+1.8%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus DVA.
ARQT leads by 17 points.
ARQT scores 70/100 (Buy) versus DVA at 53/100 (Watch).
ARQT Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.80 across 5 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
DVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 3 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — high leverage (debt-to-equity 77.99) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 13.6 is inexpensive for the broad market — Value
- ROE of 181.2% shows genuine earnings power backing the valuation — Value
- 3 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 101.2x prices in significant intangible value — Value
- Debt-to-equity of 77.99 adds balance-sheet risk to the value case — Value
- RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup) — Technical